Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756

Watchlist Manager
Shandong Xinhua Pharmaceutical Co Ltd Logo
Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
Watchlist
Price: 13.88 CNY -1.98% Market Closed
Market Cap: 6.8B CNY

Shandong Xinhua Pharmaceutical Co Ltd's latest stock split occurred on Jul 27, 2018

The company executed a 1-for-1 stock split, meaning that for every share held, investors received 1 new share.

Before the split, Shandong Xinhua Pharmaceutical Co Ltd traded at 8.0769 per share. Afterward, the share price was about 7.5192.

The adjusted shares began trading on Jul 27, 2018. This was the only stock split in Shandong Xinhua Pharmaceutical Co Ltd's history.

Last Splits:
Jul 27, 2018
1-for-1
Pre-Split Price
7.6413 8.0769
Post-Split Price
7.5192
Before
After
Last Splits:
Jul 27, 2018
1-for-1

Shandong Xinhua Pharmaceutical Co Ltd
Stock Splits History

Shandong Xinhua Pharmaceutical Co Ltd Stock Splits Timeline
Jul 27, 2018
Jul 27, 2018
Split 1-for-1
/1
Pre-Split Price
7.6413 8.0769
Post-Split Price
7.5192
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 22, 2025
Seres Therapeutics Inc
SWB:1S9
1-for-20
/20
0.3216 6.432 EUR 6.432 6.432 EUR
Apr 22, 2025
G
Golden Shield Resources Inc
F:4LE0
1-for-10
/10
0.011 0.11 EUR 0.11 0.11 EUR
Apr 22, 2025
E
EV Advanced Material Co Ltd
KOSDAQ:131400
911-for-787
x1.1575603557814
1493 1493 KRW 1439 1439 KRW
Apr 22, 2025
Seres Therapeutics Inc
F:1S9
1-for-20
/20
0.01 0.2 EUR 0.2 0.2 EUR
Apr 22, 2025
G
Golden Shield Resources Inc
OTC:GSRFF
1-for-10
/10
0.024 0.24 USD 0.24 0.24 USD
Load More

Shandong Xinhua Pharmaceutical Co Ltd
Glance View

Market Cap
6.8B CNY
Industry
Pharmaceuticals

In the industrious province of Shandong, China, Shandong Xinhua Pharmaceutical Co. Ltd. emerges as a notable player in the pharmaceutical landscape. Established in 1943, the company has grown into a comprehensive pharmaceutical enterprise with a significant presence both domestically and internationally. At its core, Shandong Xinhua is devoted to the research, development, and manufacture of active pharmaceutical ingredients (APIs), finished dosages, and chemical intermediates. The firm's strength lies in its diverse range of products, with pain management and anti-infectives being standout categories. Their strategic focus on innovation is evident in their state-of-the-art R&D facilities, which fuel continuous product development, ensuring they meet high regulatory standards and cater to evolving market demands. The journey of Shandong Xinhua is one of strategic evolution, with a steadfast commitment to quality and sustainability. This narrative is reflected in their robust revenue streams derived from both domestic sales and the lucrative export markets across over 50 countries. The company's business model hinges on creating value through efficient manufacturing processes and leveraging economies of scale, which enhances their competitive edge in the global market. With an eye on future growth, they've also been investing in digitalization to streamline operations and enhance productivity. As the pharmaceutical sector continues to expand, Shandong Xinhua Pharmaceutical Co. Ltd. is poised to capitalize on emerging opportunities, underpinned by its solid foundation and innovative thrust.

Intrinsic Value
19.74 CNY
Undervaluation 30%
Intrinsic Value
Price
Back to Top